NCT03370367View on ClinicalTrials.gov

Double Blind Phase III Trial of Effects of Low Dose 13-Cisretinoic Acid on Prevention of Second Primaries in Stages I-II Head and Neck Cancer

PHASE3CompletedINTERVENTIONAL

Enrollment

189

Participants

Timeline

Start Date

May 15, 1989

Primary Completion Date

January 15, 1999

Study Completion Date

April 14, 2015

Conditions

Stage I-II Head and Neck Cancer

Interventions

DRUG

13-cis retinoic acid

Taken daily.

OTHER

Placebo

Placebo

All Listed Sponsors

lead

Eastern Cooperative Oncology Group

NETWORK